Prostate cancer enhanced mRNA detection assay in whole blood as predictive biomarker of tumor sensitivity to targeted androgen inhibition for men with metastatic castration-resistant prostate cancer (mCRPC).

Daniel C. Danila,Shibu Thomas,Yashoda Rajpurohit,Amrita Herkal,Michael Gormley,Erica Simone Dayan,Nicole A. Schreiber,Martin Fleisher,Deborah Ricci,Howard I. Scher

Prostate cancer enhanced mRNA detection assay in whole blood as predictive biomarker of tumor sensitivity to targeted androgen inhibition for men with metastatic castration-resistant prostate cancer (mCRPC).

2016

Daniel C. Danila
Shibu Thomas
Yashoda Rajpurohit
Amrita Herkal
Michael Gormley
Erica Simone Dayan
Nicole A. Schreiber
Martin Fleisher
Deborah Ricci
Howard I. Scher

5038Background: Enzalutamide (ENZ) and abiraterone + prednisone (AA) have transformed the care of pts with mCRPC. Qualified predictive biomarkers are needed to guide treatment selections. Studies o...

Keywords:

Androgen
Pathology
Whole blood
Prostate cancer
Cancer research
Castration
Biomarker (medicine)
Medicine
Enzalutamide
predictive biomarker
Oncology
Messenger RNA
castration resistant
Internal medicine
Prednisone

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations